Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Chuikyo Approves Promotion of Mixed Healthcare in National Strategic Special Zones, Reduction of Review Period by Half
March 14, 2014
- Committee for Assessment of Advanced Healthcare Services Holds 1st Meeting to Expedite Off-label Use of Anticancer Drugs under Senshin-iryo B program
March 13, 2014
- MHLW Notifies Prefectures of Rules on Online OTC Drug Sales
March 12, 2014
- Settlements Allowing Retroactive Modifications of Transaction Price Not Regarded as Settlements under New Price Cut Rule
March 12, 2014
- HPB’s Economic Affairs Division to Set Up Study Group to Monitor Progress of Roadmap to Promote Generic Drug Use
March 12, 2014
- Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
- PAFSC’s Committee on Blood Programs Approves Standard Prices of Raw Plasma to Rise in FY2014 Due to Hike in Consumption Tax
March 11, 2014
- PMDA Raises Caution on Teratogenicity of Keratosis Treatment Tigason, Urges Use Only in Serious Cases
March 11, 2014
- Kitasato Daiichi Cannot Secure Flu Vaccine Production Capacity for 20 Million People by State Project Deadline
March 10, 2014
- Opposition Lawmaker Throws Doubts on Key Premium Given to Dellegra
March 7, 2014
- MHLW to Issue Notification Asking Doctors to Refrain from Selecting “No Substitution” Checkbox When Writing Prescriptions
March 7, 2014
- Basic Fees Paid to Pharmacies and Hospitals with Low Price Settlement Rates to Be Reduced under the New Rule from January 2015
March 7, 2014
- Pharmacists Will Be Required to Explain Reasons for Not Dispensing Generics in Case of Generic Name Prescriptions from FY2014
March 7, 2014
- MHLW to Set Up Study Group to Discuss Legislation to Regulate Clinical Research “by April at the Latest”
March 6, 2014
- Market Share of Generics Stood at 46.9% Based on New Calculation Method as of September Last Year: MHLW
March 6, 2014
- Januvia/Glactiv to See 10.1% Price Cut Due to Re-Pricing Following Market Expansion
March 6, 2014
- MHLW to Conduct Hearings with Takeda on Blopress Research Data
March 5, 2014
- Pfizer No. 1 Premium Getter in FY2014 Revision, Non-Japanese Makers Sweep Top 10 List
March 5, 2014
- FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
- MHLW to Draft Guidelines to Prevent Misuse of Research Funding, Improper Research Activities
March 5, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…